Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GCK | P35557 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28605511 | 0.78 | PPARG (0.35) | HCRTR2SLC6A3PDE2A | |
| SCHEMBL25107612 | 0.76 | LMNA (0.42) | CES2CES1ALDH1A1 | |
| SCHEMBL25108748 | 0.76 | CES2 (0.37) | GAACES2CES1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13171953 | 0.75 | LMNA (0.41) | GAAALDH1A1POLB | |
| SCHEMBL21862473 | 0.74 | PDE4B (0.43) | PDE4APDE4BPDE4CPDE4DSCN9A | |
| SCHEMBL8894645 | 0.71 | CES2 (0.46) | SLC6A3CES2CES1ALDH1A1SMN1; SMN2 | |
| SCHEMBL8893830 | 0.70 | CES2 (0.52) | SLC6A3CES2CES1POLB | |
| SCHEMBL21804583 | 0.70 | HSP90AB1 (0.46) | HCRTR2GAAALDH1A1SMN1; SMN2SCN9A | |
| SCHEMBL28596253 | 0.70 | USP9X (0.38) | HCRTR2SLC6A3PDE2A | |
| SCHEMBL25107633 | 0.68 | ALDH1A1 (0.46) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. | 2021-11-11 | — | — | US | disclosed |
| EP-3852792-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| EP-3852790-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | Forma Therapeutics, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113164571-A | Inhibition of ubiquitin-specific peptidase 9X | 福马治疗股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2021055668-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| WO-2020191022-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191022-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020061252-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061252-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2020061261-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | FORMA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346356-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, RBX1, USP19 | HCRTR2 4412/4885SLC6A3 4600/4885GAA 1360/4885 |
| US-20230065368-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X | USP9X, USP19, USP39 | HCRTR2 4788/4885SLC6A3 3742/4885GAA 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.